C12N 2770/20021
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2770/20021 (Viruses as such) appears on 63 US grants and 127 published applications in this corpus.
Search patents in C12N- Granted patents
- 63
- Published applications
- 127
- Assignees
- 93
- Inventors
- 392
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 4 |
| 2006 | 0 | 5 |
| 2007 | 1 | 2 |
| 2008 | 4 | 3 |
| 2009 | 2 | 1 |
| 2010 | 3 | 2 |
| 2011 | 1 | 2 |
| 2012 | 1 | 1 |
| 2013 | 2 | 0 |
| 2014 | 2 | 2 |
| 2015 | 1 | 4 |
| 2016 | 0 | 7 |
| 2017 | 3 | 4 |
| 2018 | 7 | 4 |
| 2019 | 3 | 3 |
| 2020 | 3 | 4 |
| 2021 | 4 | 8 |
| 2022 | 6 | 10 |
| 2023 | 5 | 25 |
| 2024 | 5 | 15 |
| 2025 | 1 | 16 |
| 2026 | 3 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Coronavirus vaccines compositions and method of using same8 Sep 2026US 12,728,159 B2Loyola University of Chicago
- Modified S2 subunit of the coronavirus spike protein14 Apr 2026US 12,600,751 B2
- Particles, DNA and RNA27 Jan 2026US 12,533,406 B2Novoscope IP Limited
- Viral preparations and methods for treating and modulating mitochondrial effects of coronavirus infections13 May 2025US 12,297,460 B1
- CRISPR-based programmable RNA editing12 Nov 2024US 12,139,731 B2National Institutes of Health (Nih), U.S. Dept. of Health and Human Services (Dhhs), U.S. Government
- Noble cold-adapted attenuated mers-cov23 Apr 2026US 2026/0108596 A1Pioneervaccine Inc.
- Method for producing a computational reduction vaccine12 Mar 2026US 2026/0074010 A1
- Method for manufacturing inactivated sars-cov-2 vaccine, inactivated sars-cov-2 vaccine, method for purifying sars-cov-2 or inactivated sars-cov-2, and sars-cov-2 antigen composition or inactivated sars-cov-2 antigen composition12 Feb 2026US 2026/0041762 A1KM Biologics Co., Ltd.
- Treatment methods for viral infections15 Jan 2026US 2026/0014246 A1The UAB Research Foundation
- Sars-cov-2 lacking the envelope protein as an attenuated vaccine virus against covid-1925 Dec 2025US 2025/0387467 A1Wisconsin Alumni Research Foundation
Most cited
By later US patents
- Pathogenic porcine respiratory coronavirus25US 5,419,907 AIowa State University Research Foundation, Inc. · 1995
- Coronavirus20US 10,130,701 B2The Pirbright Institute · 2018
- Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics14US 7,803,918 B2Amsterdam Institute of Viral Genomics B.V. · 2010
- Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics13US 8,835,107 B2Amsterdam Institute of Viral Genomics B.V. · 2014
- Mouse-adapted SARS-CoV-2 viruses and methods of use thereof12US 11,225,508 B1The University of North Carolina at Chapel Hill · 2022